drugset / Trial / NCT04469907
Study to Assess the Pharmacokinetics and Safety of AZD9977 in Participants With Renal Impairment
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a single dose, non-randomized, open-label, parallel group study. The study will be conducted in participants with severe renal impairment and compared with matched participants with normal renal function. The duration of the study for an individual participant from Screening to Follow-up will be approximately 5 weeks.
Timeline
- Start
- 2020-06-22
- Primary completion
- 2021-10-28
- Completion
- 2021-10-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | balcinrenone | Small molecule | — | Oral |